Skip to content
Medical Health Aged Care

ChemPartner Unveils Highly Anticipated Biology Database

ChemPartner 3 mins read

Newly-launched database offers easier access to diverse tumor models and unveils the path to pharmaceutical breakthroughs

SHANGHAI, CHINA / ACCESSWIRE / December 22, 2023 / ChemPartner, a global leader in drug discovery and development services, today announced the launch of its long-awaited Biology Database. This innovative platform serves as a centralized hub, empowering ChemPartner's clientele with seamless access to a wealth of information on the organization's cutting-edge preclinical platforms. The database includes 800+ tumor models, 30+ cancer types, 20,000 genes, 2,300+ pathways, 1,800 SoC data from literature (500 internal), and 30+ analytic modules.

ChemPartner Biology Database
ChemPartner Biology Database
Screenshot of the online Biology Database from ChemPartner

ChemPartner's renowned biology and pharmacology department, known for its vanguard oncology, immunology, CNS, and metabolic services, has curated an extensive collection of in vitro and in vivo models. The database boasts over 2,000 biochemistry assays, 800 cell lines, 500 patient-derived xenograft (PDX) models, 350 cell-derived xenograft (CDX) models, and 50 syngeneic models. Each model is meticulously characterized with comprehensive data encompassing genomics, pharmacology, histopathology, and relevant clinical information.

Cell Line Models - ChemPartner Biology Database

To ensure a smooth and efficient rollout of this substantial volume of data, the database will be introduced in stages. We are delighted to announce that the first stage, featuring cell line data, is now live on Subsequent stages will include CDX, syngeneic, and PDX models, followed by biochemistry data.

The Biology Database, a flagship online collaborative platform, prominently features the Tumor Model Database. This revolutionary resource offers an array of features, including:

  • Unified Data Hub: Integration of dispersed tumor model data into a centralized database for efficient management and retrieval, simplifying user access to diverse tumor models.
  • Detailed Annotations: Each model is accompanied by intricate annotations including genomics, pathology, and pharmacology data, enabling rapid understanding of model characteristics and suitability for specific research needs.
  • Rapid Search and Filtering: Multidimensional search and filtering capabilities empower researchers to swiftly locate models based on cancer type, genomic features, drug sensitivity, and more.
  • Data Analysis and Mining: Robust tools facilitate tasks like drug mechanism analysis and biomarker discovery through differential gene expression and drug sensitivity analyses, supporting informed research decisions.
  • Data Visualization: Intuitive charts, statistics, and visualization tools present complex data clearly and concisely, aiding in model selection and analysis.

Dr. Lilly Xu, President of Shanghai ChemPartner, expressed enthusiasm about the launch saying, "We are excited to provide our customers with access to this powerful new resource. This comprehensive database will make it easier for our customers to find and use the right models for their research, propelling drug development towards new heights with better precision, efficacy, and efficiency."


About ChemPartner

ChemPartner is a leading global CRO and CDMO providing drug discovery, development, and manufacturing services to the pharmaceutical and biotechnology industries. With a team of over 2,000 scientists across multiple countries, ChemPartner offers a comprehensive range of services including preclinical pharmacology, toxicology, drug metabolism and pharmacokinetics, chemistry development, and biologics development. For more information, please visit and connect with ChemPartner on LinkedIn, X,  and YouTube.

Contact Information

Sarah Stapleton
Marketing Director

Related Images

ChemPartner Biology Database
ChemPartner Biology Database
Screenshot of the online Biology Database from ChemPartner
Cell Line Models
Cell Line Models
Pie chart of cell line models available on the Biology Database from ChemPartner

SOURCE: ChemPartner


View the original press release on

More from this category

  • Medical Health Aged Care, Science
  • 17/07/2024
  • 14:00
De Motu Cordis

De Motu Cordis (DMC) announces plans for the next stage of development for DMC-IH1, an inhaled epinephrine drug device combination product

Brisbane, QLD – 17 July 2024 – De Motu Cordis (DMC) today announced plans for the next stage of development with its Contract Development and Manufacturing Organization (CDMO) partner, Catalent, at Catalent’s Boston, Morrisville and San Diego sites. These expansion plans encompass services from drug product manufacturing and device assembly through to commercial launch of DMC’s product, DMC-IH1. DMC-IH1 is an inhaled epinephrine drug-device combination product being developed for the treatment of anaphylaxis using a dry powder inhaler (DPI). Catalent DPI drug delivery services offer end-to-end solutions to bring customers through the entire clinical pharma journey by leveraging the commercial…

  • Medical Health Aged Care, Women
  • 17/07/2024
  • 07:00
Monash University

Study underlines the importance of supporting primary care clinicians to deliver early medical abortion and long acting reversible contraception

The impetus for additional support and training for clinicians wanting to deliver important sexual and reproductive services has received a boost with the release of Monash University-led research. Published in BMJ – Sexual and Reproductive Health, the AusCAPPS study found that GPs, nurses and pharmacists seek peer support and online resources to deliver long-acting reversible contraception (LARC) and early medical abortion (EMA) in Australian primary care.Experienced and emerging providers of LARC and EMA sought support regarding clinical issues online from AusCAPPS, which is the Australian Contraception and Abortion Primary Care Practitioner Support Network, an evidence-based virtual community of practice launched…

  • Medical Health Aged Care
  • 17/07/2024
  • 03:11
Interrad Medical, Inc.

Interrad Medical’s SecurAcath is Superior to Standard of Care in Newly Published Randomized Controlled Clinical Study

PLYMOUTH, Minn.–BUSINESS WIRE– Interrad Medical, Inc., a privately held medical device company, announces excellent results of a clinical study published in JAMA Pediatrics titled,…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.